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I fully support Rory Collins’s request that The BMJ retracts
Abramson and colleagues’ andMalhotra’s papers.1-3The authors
totally misrepresent Zhang and colleagues’ claims that statins
were causally related to side effects in 20% of statin users.4 The
two papers also imply that these side effects were not reported
in trials because trial sponsors could have influenced the results
and downplayed the drugs’ side effect profiles.
As co-chief investigator of ASCOT,5 an independently designed
and led trial, in which the data were analysed and published
independently of the funder, Pfizer, I strongly refute such
implications. In ASCOT, we detected drug related side effects
of the angiotensin converting enzyme inhibitor (cough) and the
calcium channel blocker (ankle oedema).6 So if statins were
causally related to myalgia or myopathy, why did we not detect
this in a trial of 10 000 people?7Adverse events and withdrawals
from treatment were identical in those taking placebo or statin.
Perhaps the answer is provided by a recent study, where
rechallenge of patients previously withdrawn from statin because
of myalgia, yielded the return of identical symptoms with both
statin and placebo.8
The effect of these papers2 3 is that, for the wrong reasons,
patients whose future morbidity and mortality from
cardiovascular disease would have benefited substantially from
statin therapy, will be dissuaded from taking the drugs or will
discontinue them if they are already receiving treatment.
The BMJ has taken a strong position on scientific integrity, and
its condemnation of the Lancet’s publication of the Wakefield
measles, mumps, and rubella scandal was well received. The
same principles should apply over the critical reviews of these
two statin papers. The reporting of bad science is the prerogative
of the lay press, not The BMJ.
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